Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron. In two mouse models of Parkinson’s disease, they show that Tat-βsyn-degron decreases α-synuclein aggregates and microglial activation as well as reducing neuronal da...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jack Wuyang Jin, Xuelai Fan, Esther del Cid-Pellitero, Xing-Xing Liu, Limin Zhou, Chunfang Dai, Ebrima Gibbs, Wenting He, Hongjie Li, Xiaobin Wu, Austin Hill, Blair R. Leavitt, Neil Cashman, Lidong Liu, Jie Lu, Thomas M. Durcan, Zhifang Dong, Edward A. Fon, Yu Tian Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/63d676340fd343489fc159532b920ece
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63d676340fd343489fc159532b920ece
record_format	dspace
spelling	oai:doaj.org-article:63d676340fd343489fc159532b920ece2021-12-02T12:11:51ZDevelopment of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models10.1038/s42003-021-01746-62399-3642https://doaj.org/article/63d676340fd343489fc159532b920ece2021-02-01T00:00:00Zhttps://doi.org/10.1038/s42003-021-01746-6https://doaj.org/toc/2399-3642Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron. In two mouse models of Parkinson’s disease, they show that Tat-βsyn-degron decreases α-synuclein aggregates and microglial activation as well as reducing neuronal damage and motor impairment. This study demonstrates the therapeutic potential of Tat-βsyn-degron in Parkinson’s disease treatment.Jack Wuyang JinXuelai FanEsther del Cid-PelliteroXing-Xing LiuLimin ZhouChunfang DaiEbrima GibbsWenting HeHongjie LiXiaobin WuAustin HillBlair R. LeavittNeil CashmanLidong LiuJie LuThomas M. DurcanZhifang DongEdward A. FonYu Tian WangNature PortfolioarticleBiology (General)QH301-705.5ENCommunications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biology (General) QH301-705.5
spellingShingle	Biology (General) QH301-705.5 Jack Wuyang Jin Xuelai Fan Esther del Cid-Pellitero Xing-Xing Liu Limin Zhou Chunfang Dai Ebrima Gibbs Wenting He Hongjie Li Xiaobin Wu Austin Hill Blair R. Leavitt Neil Cashman Lidong Liu Jie Lu Thomas M. Durcan Zhifang Dong Edward A. Fon Yu Tian Wang Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
description	Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron. In two mouse models of Parkinson’s disease, they show that Tat-βsyn-degron decreases α-synuclein aggregates and microglial activation as well as reducing neuronal damage and motor impairment. This study demonstrates the therapeutic potential of Tat-βsyn-degron in Parkinson’s disease treatment.
format	article
author	Jack Wuyang Jin Xuelai Fan Esther del Cid-Pellitero Xing-Xing Liu Limin Zhou Chunfang Dai Ebrima Gibbs Wenting He Hongjie Li Xiaobin Wu Austin Hill Blair R. Leavitt Neil Cashman Lidong Liu Jie Lu Thomas M. Durcan Zhifang Dong Edward A. Fon Yu Tian Wang
author_facet	Jack Wuyang Jin Xuelai Fan Esther del Cid-Pellitero Xing-Xing Liu Limin Zhou Chunfang Dai Ebrima Gibbs Wenting He Hongjie Li Xiaobin Wu Austin Hill Blair R. Leavitt Neil Cashman Lidong Liu Jie Lu Thomas M. Durcan Zhifang Dong Edward A. Fon Yu Tian Wang
author_sort	Jack Wuyang Jin
title	Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
title_short	Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
title_full	Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
title_fullStr	Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
title_full_unstemmed	Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models
title_sort	development of an α-synuclein knockdown peptide and evaluation of its efficacy in parkinson’s disease models
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/63d676340fd343489fc159532b920ece
work_keys_str_mv	AT jackwuyangjin developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT xuelaifan developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT estherdelcidpellitero developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT xingxingliu developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT liminzhou developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT chunfangdai developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT ebrimagibbs developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT wentinghe developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT hongjieli developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT xiaobinwu developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT austinhill developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT blairrleavitt developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT neilcashman developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT lidongliu developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT jielu developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT thomasmdurcan developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT zhifangdong developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT edwardafon developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels AT yutianwang developmentofanasynucleinknockdownpeptideandevaluationofitsefficacyinparkinsonsdiseasemodels
_version_	1718394577531961344

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models

Ejemplares similares